01Evotec reported Q2 2026 earnings per share of -$0.15, missing the consensus estimate of -$0.06 by $0.09, and revenue of $166.8M versus the expected $212.4M, representing a 150% miss on earnings.
02The stock trades at $2.00 with a market capitalization of $1.1B, and the significant earnings miss is likely to pressure the stock as investors reassess growth assumptions.
03Evotec has a pattern of recent earnings misses, including a -603.8% surprise in Q1 2026 and a -106.5% surprise in Q3 2025, suggesting ongoing operational challenges rather than isolated issues.
Earnings Results
Evotec (NASDAQ:EVO) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.15, missing the consensus estimate of $-0.06 by $0.09 per share. Revenue came in at $166.8M, missing the estimate of $212.4M.
Company Overview
Evotec's stock moved following the earnings release. The stock currently trades at $2.00 with a market capitalization of $1.1B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 150% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Evotec should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.